It's Showtime for AstraZeneca
AstraZeneca (ISE: AZN) is expected to report Q4 earnings on Jan. 31. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AstraZeneca's revenues will contract -16.7% and EPS will contract -11.8%.
The average estimate for revenue is $7.21 billion. On the bottom line, the average EPS estimate is $1.42.
Last quarter, AstraZeneca tallied revenue of $6.68 billion. GAAP reported sales were 19% lower than the prior-year quarter's $8.21 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.51. GAAP EPS of $1.21 for Q3 were 52% lower than the prior-year quarter's $2.54 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 81.1%, 70 basis points better than the prior-year quarter. Operating margin was 36.1%, 1,850 basis points worse than the prior-year quarter. Net margin was 22.8%, 1,950 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $28.05 billion. The average EPS estimate is $6.20.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 46 members out of 51 rating the stock outperform, and five members rating it underperform. Among one CAPS All-Star picks (recommendations by the highest-ranked CAPS members), one give AstraZeneca a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AstraZeneca is hold, with an average price target of $46.80.
Can your portfolio provide you with enough income to last through retirement? You'll need more than AstraZeneca. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add AstraZeneca to My Watchlist.
The article It's Showtime for AstraZeneca originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.